KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBT Margin (2016 - 2025)

Historic EBT Margin for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to 15.6%.

  • Travere Therapeutics' EBT Margin rose 1027800.0% to 15.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.32%, marking a year-over-year increase of 1510800.0%. This contributed to the annual value of 137.45% for FY2024, which is 1215100.0% up from last year.
  • As of Q3 2025, Travere Therapeutics' EBT Margin stood at 15.6%, which was up 1027800.0% from 11.13% recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' EBT Margin registered a high of 56.1% during Q4 2021, and its lowest value of 348.94% during Q1 2022.
  • Moreover, its 5-year median value for EBT Margin was 128.55% (2024), whereas its average is 165.68%.
  • Its EBT Margin has fluctuated over the past 5 years, first surged by 2955800bps in 2021, then tumbled by -3477700bps in 2022.
  • Quarter analysis of 5 years shows Travere Therapeutics' EBT Margin stood at 56.1% in 2021, then plummeted by -620bps to 291.67% in 2022, then surged by 33bps to 196.47% in 2023, then soared by 59bps to 80.68% in 2024, then soared by 119bps to 15.6% in 2025.
  • Its last three reported values are 15.6% in Q3 2025, 11.13% for Q2 2025, and 50.39% during Q1 2025.